Sydney, Australia (CU)_ According to MGC Pharma Ltd, the company was approved by the Indian authorities and granted permission to import its phytomedicine CimetrA into the nation. According to the firm, the approval highlighted the last step towards getting emergency-use authorization for the treatment of Coronavirus patients.
Roby Zomer, co-founder and managing director of MGC, expressed delight over the new accomplishment. He said, “We are pleased to have secured a license to import CimetrA as an Emergency Use Drug in India, and hope that we can secure approval swiftly to expand its availability to a much wider patient base”. He added, “India has been acutely affected by the COVID-19 pandemic and we believe that CimetrA can make an important difference in treating the symptoms of COVID-19 and alleviate patient suffering.”
The company said in the same statement that it has selected…
